Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Dec 19.

Published in final edited form as: Pediatr Neurol. 2015 Apr 9;53(1):31–46. doi: 10.1016/j.pediatrneurol.2015.03.019

Table 8.

Event-Free and Overall Survival Rates Among All Patients.

			5-year EFS			5-year OS

		# Patients	%	SE	P value^*	%	SE	P value^*
All	Eligible	92	43.9	5.2		63.6	5.1
Age	< 12 months	13	38.5	13.5	.794	53.9	13.9	.31
	12–<24 months	45	45.3	7.5		63.4	7.3
	24–36 months	34	44.1	8.5		67.7	8.0
Gender	Male	46	52.1	7.4	.054	71.6	6.7	.052
	Female	46	35.6	7.1	.054	55.4	7.4	.052
M-Stage	M0	67	51.5	6.2	.026	68.2	5.7	.062
	M1+	22	27.3	9.5	.026	54.6	10.6	.062
	Missing	3
Resection	GTR/No Residual	47	54.4	7.3	.0065	75.9	6.3	.0034
	<GTR or Residual	41	28.9	7.1		48.7	7.8
	Missing	4
Site	Supratentorial	32	34.4	8.4	.082	53.1	8.8	.0426
	Infratentorial	60	49.1	6.5	.082	69.1	6.1	.0426
Histology	Medulloblastoma (all)	36	60.0	8.3	.163	68.3	7.9	.034
	Ependymoma	21	38.1	10.6		81.0	8.6
	SPNET/Pineoblastoma	17	29.4	11.1		41.2	11.9
	AT/RT	8	37.5	17.1		62.5	17.1
	Other Eligible	10	30.0	14.5		50.0	15.8

^*

P values from log-rank test